Tuesday, August 19, 2025
StockstToday.com Logo
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Goldman Sachs Analyst Maintains Sell Rating on Overvalued HR Block

Elaine Mendonca by Elaine Mendonca
February 7, 2024
in Breaking News
0
SO stock news
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

On February 7, 2024, George Kelly, an analyst at Goldman Sachs, expressed a pessimistic view on H&R Block (NYSE:HRB). Despite raising the price target from $34 to $38, Kelly maintained a “Sell” rating on the stock. This decision signifies Goldman Sachs’ belief that H&R Block is currently overvalued and might struggle to meet expectations in the coming days.

HRB Stock Shows Mixed Performance with Significant Drop in Share Price: Analysis and Insights

On February 7, 2024, HRB stock, the ticker symbol for H&R Block, showcased a mixed performance as it traded near the top of its 52-week range but experienced a significant drop in its share price. According to data sourced from CNN Money, HRB was trading above its 200-day simple moving average, indicating a positive trend in the stock’s price momentum.

The day’s trading session saw a notable price change for HRB shares, with a decrease of $3.03 since the market last closed. This represented a drop of 6.39% in the stock’s value.

The stock opened at $45.42, which was $1.92 lower than its previous closing price. This lower opening price may have contributed to the overall downward movement in HRB’s share value throughout the day.

Despite the drop in share price, it is worth noting that HRB was still trading near the top of its 52-week range. This indicates that the stock had been performing well in the past year, reaching higher price levels than it had previously.

Furthermore, the fact that HRB was trading above its 200-day simple moving average suggests that the stock had been on an upward trajectory in terms of its long-term price trend.

Investors and analysts would likely be monitoring HRB closely following the significant drop in share price on February 7, 2024. They would be interested in understanding the factors behind the decline and assessing whether it was a temporary setback or a sign of a more significant issue with the company.

It is important to note that stock prices can be influenced by various factors, including market conditions, company-specific news, and investor sentiment. Therefore, it is advisable for investors to conduct thorough research and analysis before making any investment decisions based on stock performance alone.

HRB Stock Performance: Mixed Figures in Financials Raise Concerns for Investors

HRB stock experienced mixed performances on February 7, 2024, as the company’s financials revealed contrasting figures. The data highlights the total revenue, net income, and earnings per share (EPS) for the past year and the first quarter of the year.

Starting with the total revenue, HRB reported $3.47 billion in total revenue over the past year, which remained flat compared to the previous year. However, there was a significant decrease of 82.19% in total revenue since the last quarter, dropping to $183.80 million.

Moving on to the net income, HRB recorded a net income of $551.43 million over the past year, which held flat compared to the previous year. However, the net income took a sharp decline of 153.86% since the last quarter, resulting in a negative net income of -$163.05 million.

Examining the earnings per share (EPS), HRB reported an EPS of $3.51 over the past year, indicating a 9.07% increase compared to the previous year. However, the EPS plummeted by 157.05% since the last quarter, reaching -$1.12.

Considering these financial figures, HRB stock performances on February 7, 2024, may be influenced by the contrasting trends. The flat total revenue and net income compared to the previous year could provide some stability to the stock, but the significant declines in both metrics since the last quarter may overshadow any positive sentiment.

Investors and analysts will closely monitor HRB’s ability to rebound from the negative net income and the subsequent impact on the EPS. Additionally, HRB’s future strategies and initiatives to address the decline in revenue will play a crucial role in determining the stock’s performance in the coming months.

It is important to note that stock performances are influenced by various factors, including market conditions, industry trends, and company-specific developments. Therefore, investors should conduct thorough research and analysis before making any investment decisions related to HRB stock.

Tags: HRB
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Stock Exchange

Evaxion Biotech AS Regains Compliance with Nasdaq Listing Rule 5550a2

Electronic and Electrical Equipment Markets and money

Herc Holdings Increases Quarterly Dividend by 5 to Reward Shareholders

Biotechnology Stock Market Today (1)

One Stop Systems Inc Ships Gen 5 4U Pro Accelerator System to Prominent Provider of Composable Infrastructure

Recommended

Aramark Stock

Aramark Strengthens Financial Position Through Strategic Debt Refinancing

16 hours ago
TMO stock news

Strategic Acquisition and Dividend Declaration Highlight SG Americas Securities’ Influence in the Financial Sector and First Commonwealth Financial’s Commitment to Shareholders

2 years ago
Investings on laptops and finances

Analyzing GoHealths Earnings and Stock Performance

1 year ago
Biotechnology Stock Bull Market

Autodesk Acquires X2Xs PIX Business Revolutionizing the Entertainment Sector

2 years ago

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • ETF
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

Topics

AAL AAPL ABNB ADBE ADSK ALB AMD AMZN AVGO BA C CCL CELH COIN COST CRWD CTVA DELL DFS DIS DLR DLTR DWAC GM GRFS IBM INTC JPM KSS LLY META MSFT NFLX NVDA NVO ORCL PARA PLTR PLUG QCOM SMCI TGT TSLA UNH VZ
No Result
View All Result

Highlights

Broadcom Executives Cash Out Amid Diverging Market Sentiment

Kodak’s Survival Hangs in the Balance as Debt Crisis Deepens

Iovance Secures Landmark Canadian Approval for Breakthrough Cancer Therapy

Poland’s Economic Momentum Fuels Growth Prospects for iShares MSCI Poland ETF

Rio Tinto’s Lithium Power Play: How a $6.7B Acquisition Reshapes the Battery Materials Race

Warren Buffett Bets Big on Troubled Healthcare Giant UnitedHealth

Trending

CoreCivic Stock
Stocks

Leadership Shift and Lucrative Government Deal Signal Potential Turnaround for CoreCivic

by Andreas Sommer
August 19, 2025
0

The embattled private prison operator CoreCivic (NYSE: CXW) may be poised for a resurgence as two major...

Savara Stock

Savara Biotech Nears Pivotal Moment with Promising Lung Disease Treatment

August 19, 2025
Agios Stock

Agios Pharmaceuticals Navigates Financial Turbulence Amid Promising Clinical Developments

August 19, 2025
Broadcom Stock

Broadcom Executives Cash Out Amid Diverging Market Sentiment

August 19, 2025
Eastman Kodak Stock

Kodak’s Survival Hangs in the Balance as Debt Crisis Deepens

August 19, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Recent News

  • Leadership Shift and Lucrative Government Deal Signal Potential Turnaround for CoreCivic August 19, 2025
  • Savara Biotech Nears Pivotal Moment with Promising Lung Disease Treatment August 19, 2025
  • Agios Pharmaceuticals Navigates Financial Turbulence Amid Promising Clinical Developments August 19, 2025

Categories

  • Analyst Ratings
  • Breaking News
  • Business & Industry Trends
  • ETF
  • Market News
  • Stock Picks
  • Stock Targets
  • Stocks
  • Uncategorized

© 2024 Stocks Today

No Result
View All Result
  • Home
  • Breaking News
  • Business & Industry Trends
  • Market News
  • Analyst Ratings

© 2023 StocksToday.com